| Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma (NCT06892054) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2025-08-08 |
| Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer (NCT06207656) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2024-04-16 |
| Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations (NCT05659914) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2022-11-28 |
| Spanish Registry of Digestive Tumours RETUD (NCT06711211) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2020-12-23 |
| Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (NCT03635021) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2018-10-15 |
| Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen (NCT03279289) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2017-10-25 |
| Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms (NCT02970916) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2016-11-01 |
| Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC (NCT02835924) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2016-07-01 |
| Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma (NCT02504333) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2015-07-01 |
| Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab (NCT02175654) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2014-06-01 |
| Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer (NCT01875380) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2013-06-01 |
| Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques (NCT01704703) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2012-10-01 |
| Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells (NCT01640405) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2012-07-01 |
| Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (NCT01640444) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2012-07-01 |
| Axitinib as Maintenance Treatment in Patients With Metastatic CRC (NCT01483638) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2012-02-01 |
| Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer (NCT01303029) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2011-02-01 |
| Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours (NCT01161316) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2010-08-01 |
| Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer (NCT01126112) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2010-05-01 |
| Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer (NCT01071655) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2010-02-01 |
| Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer (NCT01043484) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2009-12-01 |
| Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA) (NCT00958386) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2009-08-01 |
| Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases (NCT00885885) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2009-05-01 |
| Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients (NCT00875771) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2009-04-01 |
| Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status (NCT00733616) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2008-11-01 |
| Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer. (NCT00531115) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2007-11-01 |
| Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC (NCT00475293) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2007-05-01 |
| A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma (NCT00733889) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2006-12-01 |
| Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients (NCT00335595) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2006-07-01 |
| Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer (NCT00202787) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2005-02-01 |
| Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer (NCT00202774) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2002-04-01 |